Cargando…
Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
The multireceptor tyrosine kinase inhibitor sorafenib is a Food and Drug Administration-approved first-line drug for the treatment of advanced liver cancer that can reportedly extend overall survival in patients with advanced hepatocellular carcinoma (HCC). Primary and acquired resistance to sorafen...
Autores principales: | He, Wubin, Huang, Xiaoxu, Berges, Bradford K., Wang, Yue, An, Ni, Su, Rongjian, Lu, Yanyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946852/ https://www.ncbi.nlm.nih.gov/pubmed/33716742 http://dx.doi.org/10.3389/fphar.2021.615889 |
Ejemplares similares
-
Editorial: Treatment of Alzheimer’s disease-discovery of natural products based on neurite outgrowth and neuroprotection
por: Yang, Zhiyou, et al.
Publicado: (2022) -
Neurite Outgrowth Inhibitors in Gliotic Tissue
por: Nieto-Sampedro, M., et al.
Publicado: (1992) -
Research advances on neurite outgrowth inhibitor B receptor
por: Zhang, Rui, et al.
Publicado: (2020) -
The Effects of Hematopoietic Growth Factors on Neurite Outgrowth
por: Su, Ye, et al.
Publicado: (2013) -
Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models
por: Chen, Ying-Jie, et al.
Publicado: (2022)